Review summary
Teaching objective: Care for a 48-year-old woman with a painful swollen jaw from a dental abscess, and type 2 diabetes found on screening, as current guidance advises and without weight stigma: recognize the warning signs of spreading odontogenic infection; give an NSAID with acetaminophen for dental pain and no opioid; withhold antibiotics when the abscess is localized, there is no systemic involvement and definitive treatment is available the next day (ADA 2019); arrange urgent drainage and extraction; diagnose diabetes from two abnormal results in one sample; start metformin, then add a GLP-1 receptor agonist chosen for weight and glucose (ADA Standards of Care 2026), with an SGLT2 inhibitor not indicated without kidney or heart disease; start a statin as the Standards advise for adults 40 to 75 with diabetes; screen for eye, foot and kidney complications; explain the two-way link between periodontitis and diabetes and arrange periodontal therapy; manage knee osteoarthritis with exercise and a topical NSAID; and keep up cancer screening by age (mammography, colorectal and cervical) and bone health, without a search for bone cancer when nothing in the modern episode points to one. The modern episode is a teaching case, not a claim about her real illnesses, which cannot be known from ancient remains whose identity is debated.
Historical timeline
| Date | Event | Claims |
|---|---|---|
| About 1507 BC (very uncertain) | Born, daughter of Thutmose I; the year is a rough estimate. | CLM-0005, CLM-0001, CLM-0003 |
| About 1479 BC | On the death of Thutmose II, regent for the young Thutmose III. | CLM-0002 |
| About 1473 BC (year 7 of Thutmose III) | Rules as king, jointly with Thutmose III. | CLM-0002 |
| About 1458 BC (year 22 of Thutmose III) | Dies; cause unknown. | CLM-0004 |
| No earlier than about 1438 BC (year 42 of Thutmose III) | Her monuments begin to be effaced and recarved. | CLM-0006 |
| 2007 | Mummy KV60A announced as hers; CT findings reported; the identification is debated. | CLM-0007, CLM-0008, CLM-0009, CLM-0010, CLM-0011 |
| 2011 | University of Bonn reports a carcinogen in a lotion flask bearing her name. | CLM-0012 |
Evidence claims
D = documented, R = retrospective, S = synthetic.
| Grade | Claim | Certainty | Sources |
|---|---|---|---|
| D | Hatshepsut was a daughter of the king Thutmose I and became the chief queen of Thutmose II. History only. |
confirmed | Dorman PF. Hatshepsut: Wicked Stepmother or Joan of Arc? Oriental Institute News and Notes 168 (Winter 2001) supports |
| D | After the death of Thutmose II she acted as guardian and regent for the young Thutmose III, her nephew and stepson; by his seventh regnal year she had taken the public role of a king, while still referred to with feminine forms. Anchors her modern role as the head of a large public authority. |
confirmed | Dorman PF. Hatshepsut: Wicked Stepmother or Joan of Arc? Oriental Institute News and Notes 168 (Winter 2001) supports |
| D | She claimed to have been born of a union between her mother and the god Amun-Ra, and looked to her father Thutmose I as the source of her kingship. History only. |
confirmed | Egypt and Sudan Newsletter 1 (2014): Pharaoh: King of Egypt supports Dorman PF. Hatshepsut: Wicked Stepmother or Joan of Arc? Oriental Institute News and Notes 168 (Winter 2001) supports |
| D | Her dates follow different chronologies: The Metropolitan Museum of Art dates objects of her joint reign with Thutmose III to about 1473 to 1458 BCE, and the British Museum gives her dates as 1479 to 1457 BC. She died in the twenty-second regnal year of Thutmose III. Dates are approximate; the record uses about 1458 BC for her death. |
probable | Seated Statue of Hatshepsut (Rogers Fund, 1929), collection record: ca. 1473–1458 BCE, joint reign of Hatshepsut and Thutmose III, Dynasty 18, New Kingdom supports Egypt and Sudan Newsletter 1 (2014): Pharaoh: King of Egypt supports Dorman PF. Hatshepsut: Wicked Stepmother or Joan of Arc? Oriental Institute News and Notes 168 (Winter 2001) supports HISTMED Master Roster v3 context |
| R | Her birth year is not recorded. An age of about 50 at death, suggested by study of the mummy identified as hers, would place her birth about 1507 BC; this is a rough estimate. Used only to set an approximate, very uncertain birth year. |
possible | Rose M. Hatshepsut Found; Thutmose I Lost supports HISTMED Master Roster v3 context |
| D | No earlier than the forty-second year of Thutmose III, at least twenty years after her death, a program began to efface and recarve her monuments. History only. |
confirmed | Dorman PF. Hatshepsut: Wicked Stepmother or Joan of Arc? Oriental Institute News and Notes 168 (Winter 2001) supports |
| D | In 2007 Zahi Hawass announced that KV60A, the mummy of an obese woman left on the floor of tomb KV60 in the Valley of the Kings, was Hatshepsut. The identification rested on CT scans, above all on a molar found in a small chest inscribed with her name from the royal cache DB320, which fitted a gap in KV60A's jaw where only one root of a molar remained. Documents the announcement and its basis, not the identity itself. |
confirmed | Rose M. Hatshepsut Found; Thutmose I Lost supports |
| R | The identification is debated: any link between these mummies and the inscribed chest is uncertain, the consensus cited is that the tooth probably broke after death rather than being extracted in life, the DNA results were preliminary, and identifications of royal mummies of this dynasty are often unclear. Every finding on KV60A may not be hers. |
disputed | Rose M. Hatshepsut Found; Thutmose I Lost supports Habicht ME, Bouwman AS, Rühli FJ. Identifications of ancient Egyptian royal mummies from the 18th Dynasty reconsidered. Am J Phys Anthropol 2016;159(Suppl 61):S216-S231 (PMID 26808107) supports |
| R | The CT scans of KV60A were reported to show a woman of about 50, about five feet tall and greatly overweight, with severe dental disease (missing teeth, root remnants, bone eroded at root tips by infection, and severe gum disease), and osteoarthritis and osteoporosis; a burst abscess with spreading infection was suggested as a cause of death. Findings on remains whose identity is debated, reported in a magazine and a documentary fact sheet rather than a peer-reviewed paper. Not linked to the modern episode, which is set before her death. |
possible | Rose M. Hatshepsut Found; Thutmose I Lost supports |
| R | A lesion in the left iliac bone of KV60A was read by the radiologist Ashraf Selim as more likely a metastatic deposit from another cancer than a primary bone tumour, which could not be totally excluded. Retrospective; no cancer is diagnosed in the modern episode. |
possible | Rose M. Hatshepsut Found; Thutmose I Lost supports |
| R | Diabetes has been proposed for KV60A on circumstantial grounds; the radiologist called it a theory that cannot be confirmed. Retrospective; the modern diabetes is a synthetic screening finding, not linked to this claim. |
disputed | Rose M. Hatshepsut Found; Thutmose I Lost supports |
| R | In 2011 the University of Bonn reported that a flask in its Egyptian Museum inscribed with her name held the dried residue of a skin lotion or medication (palm oil, nutmeg apple oil, unsaturated fatty acids and hydrocarbons from creosote and asphalt), including benzo(a)pyrene, a strong carcinogen, and suggested that she may have exposed herself to it over years. A hypothesis from a press release; no study is cited, and the flask's use by her is inferred. |
possible | Deadly medication? (University of Bonn press release) supports |
Modern synthetic problem list
| Grade | Problem | Clinical status | Verification | Placement | Historical claims |
|---|---|---|---|---|---|
| S | Painful swelling of the left lower jaw for four days, after a throbbing toothache for three weeks under a broken lower left molar; low-grade temperature, no trismus, no swelling of the floor of the mouth or neck; dental abscess suspected | resolved | confirmed | active | |
| S | Acute periapical abscess of the lower left first molar (tooth 19), non-restorable, with a localized buccal vestibular swelling and no spread to fascial spaces; drained and extracted | resolved | confirmed | active | |
| S | Type 2 diabetes found on screening (hemoglobin A1c 7.6% with a random glucose of 212 mg/dL from the same sample), with thirst and waking at night to pass urine; normal kidney function and urine albumin | active | confirmed | active | |
| S | Obesity, class 2 (BMI 36.3), with type 2 diabetes and knee osteoarthritis; she wants to feel stronger and move more easily | active | confirmed | active | |
| S | Primary osteoarthritis of both knees: pain on stairs and after standing, morning stiffness under 30 minutes, crepitus, no effusion; a clinical diagnosis without imaging | active | confirmed | active | |
| S | Periodontitis, generalized, stage III, grade C (bone loss to the middle third of the roots, two molars lost earlier to gum disease, and A1c above 7% as a grade modifier) | active | confirmed | active | |
| S | Acute uncomplicated cystitis (dysuria and frequency for two days, urine dipstick positive for leukocyte esterase and nitrite, no fever or flank pain); urine culture grew Escherichia coli sensitive to nitrofurantoin; resolved | resolved | confirmed | active |
Synthetic outcome measures
| Grade | Date | Measure | Result | Coding |
|---|---|---|---|---|
| S | 2026-04-14 | Hemoglobin [Mass/volume] in Blood | 13.1 g/dL Reference 11.7-15.5 g/dL |
http://loinc.org · 718-7 |
| S | 2026-04-14 | Leukocytes [#/volume] in Blood by Automated count | 11.6 10*3/uL (high) Reference 4-11 10*3/uL |
http://loinc.org · 6690-2 |
| S | 2026-04-14 | Platelets [#/volume] in Blood by Automated count | 312 10*3/uL Reference 150-400 10*3/uL |
http://loinc.org · 777-3 |
| S | 2026-04-14 | Sodium [Moles/volume] in Serum or Plasma | 137 mmol/L Reference 135-145 mmol/L |
http://loinc.org · 2951-2 |
| S | 2026-04-14 | Potassium [Moles/volume] in Serum or Plasma | 4.2 mmol/L Reference 3.5-5.1 mmol/L |
http://loinc.org · 2823-3 |
| S | 2026-04-14 | Urea nitrogen [Mass/volume] in Serum or Plasma | 13 mg/dL Reference 7-20 mg/dL |
http://loinc.org · 3094-0 |
| S | 2026-04-14 | Creatinine [Mass/volume] in Serum or Plasma | 0.72 mg/dL Reference 0.5-1.1 mg/dL |
http://loinc.org · 2160-0 |
| S | 2026-04-14 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 103 mL/min/1.73 m² Reference >=60 mL/min/1.73 m² |
http://loinc.org · 98979-8 |
| S | 2026-04-14 | Glucose [Mass/volume] in Serum or Plasma | 212 mg/dL (high) Reference 70-139 mg/dL |
http://loinc.org · 2345-7 |
| S | 2026-04-14 | Calcium [Mass/volume] in Serum or Plasma | 9.4 mg/dL Reference 8.6-10.3 mg/dL |
http://loinc.org · 17861-6 |
| S | 2026-04-14 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 31 U/L Reference 7-35 U/L |
http://loinc.org · 1742-6 |
| S | 2026-04-14 | Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma | 84 U/L Reference 35-104 U/L |
http://loinc.org · 6768-6 |
| S | 2026-04-14 | Hemoglobin A1c/Hemoglobin.total in Blood | 7.6% (high) Reference Below 5.7% is normal; 6.5% or more is diabetes; goal below 7% for most adults with diabetes |
http://loinc.org · 4548-4 |
| S | 2026-04-14 | Cholesterol [Mass/volume] in Serum or Plasma | 214 mg/dL (high) Reference <=199 mg/dL |
http://loinc.org · 2093-3 |
| S | 2026-04-14 | Cholesterol in HDL [Mass/volume] in Serum or Plasma | 44 mg/dL (low) Reference >=50 mg/dL |
http://loinc.org · 2085-9 |
| S | 2026-04-14 | Triglyceride [Mass/volume] in Serum or Plasma | 210 mg/dL (high) Reference <=149 mg/dL |
http://loinc.org · 2571-8 |
| S | 2026-04-14 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 128 mg/dL Reference Goal below 100 mg/dL in diabetes, below 70 mg/dL at higher risk |
http://loinc.org · 13457-7 |
| S | 2026-04-14 | Albumin/Creatinine [Mass Ratio] in Urine | 18 mg/g{creat} Reference <=29 mg/g{creat} |
http://loinc.org · 9318-7 |
| S | 2026-04-14 | Thyrotropin [Units/volume] in Serum or Plasma | 2.1 mIU/L Reference 0.4-4.5 mIU/L |
http://loinc.org · 3016-3 |
| S | 2026-04-14 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 4 | http://loinc.org · 44261-6 |
| S | 2026-04-14 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 3 | http://loinc.org · 70274-6 |
| S | 2026-07-21 | Hemoglobin A1c/Hemoglobin.total in Blood | 6.6% (high) Reference Below 5.7% is normal; 6.5% or more is diabetes; goal below 7% for most adults with diabetes |
http://loinc.org · 4548-4 |
| S | 2026-07-21 | Cholesterol [Mass/volume] in Serum or Plasma | 152 mg/dL Reference <=199 mg/dL |
http://loinc.org · 2093-3 |
| S | 2026-07-21 | Cholesterol in HDL [Mass/volume] in Serum or Plasma | 48 mg/dL (low) Reference >=50 mg/dL |
http://loinc.org · 2085-9 |
| S | 2026-07-21 | Triglyceride [Mass/volume] in Serum or Plasma | 140 mg/dL Reference <=149 mg/dL |
http://loinc.org · 2571-8 |
| S | 2026-07-21 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 76 mg/dL Reference Goal below 100 mg/dL in diabetes, below 70 mg/dL at higher risk |
http://loinc.org · 13457-7 |
| S | 2026-07-21 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 27 U/L Reference 7-35 U/L |
http://loinc.org · 1742-6 |
| S | 2026-07-21 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 2 | http://loinc.org · 44261-6 |
| S | 2026-06-30 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 0 | http://loinc.org · 55758-7 |
| S | 2026-06-30 | Total score [AUDIT-C] | 1 | http://loinc.org · 75626-2 |
Synthetic vital signs
| Date | Measure | Result | LOINC | Grade |
|---|---|---|---|---|
| 2026-04-14 | Body height | 160 cm | 8302-2 | S |
| 2026-04-14 | Body weight | 93 kg | 29463-7 | S |
| 2026-04-14 | Body mass index (BMI) [Ratio] | 36.3 kg/m2 | 39156-5 | S |
| 2026-04-14 | Systolic blood pressure | 128 mm[Hg] | 8480-6 | S |
| 2026-04-14 | Diastolic blood pressure | 82 mm[Hg] | 8462-4 | S |
| 2026-04-14 | Heart rate | 92 /min | 8867-4 | S |
| 2026-04-14 | Respiratory rate | 16 /min | 9279-1 | S |
| 2026-04-14 | Body temperature | 37.6 Cel | 8310-5 | S |
| 2026-04-14 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 % | 59408-5 | S |
| 2026-04-15 | Body height | 160 cm | 8302-2 | S |
| 2026-04-15 | Body weight | 92.8 kg | 29463-7 | S |
| 2026-04-15 | Body mass index (BMI) [Ratio] | 36.2 kg/m2 | 39156-5 | S |
| 2026-04-15 | Systolic blood pressure | 126 mm[Hg] | 8480-6 | S |
| 2026-04-15 | Diastolic blood pressure | 80 mm[Hg] | 8462-4 | S |
| 2026-04-15 | Heart rate | 88 /min | 8867-4 | S |
| 2026-04-15 | Respiratory rate | 16 /min | 9279-1 | S |
| 2026-04-15 | Body temperature | 37.4 Cel | 8310-5 | S |
| 2026-04-15 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 % | 59408-5 | S |
| 2026-05-26 | Body height | 160 cm | 8302-2 | S |
| 2026-05-26 | Body weight | 91.5 kg | 29463-7 | S |
| 2026-05-26 | Body mass index (BMI) [Ratio] | 35.7 kg/m2 | 39156-5 | S |
| 2026-05-26 | Systolic blood pressure | 124 mm[Hg] | 8480-6 | S |
| 2026-05-26 | Diastolic blood pressure | 78 mm[Hg] | 8462-4 | S |
| 2026-05-26 | Heart rate | 78 /min | 8867-4 | S |
| 2026-05-26 | Respiratory rate | 14 /min | 9279-1 | S |
| 2026-05-26 | Body temperature | 36.7 Cel | 8310-5 | S |
| 2026-05-26 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 % | 59408-5 | S |
| 2026-07-21 | Body height | 160 cm | 8302-2 | S |
| 2026-07-21 | Body weight | 88.6 kg | 29463-7 | S |
| 2026-07-21 | Body mass index (BMI) [Ratio] | 34.6 kg/m2 | 39156-5 | S |
| 2026-07-21 | Systolic blood pressure | 120 mm[Hg] | 8480-6 | S |
| 2026-07-21 | Diastolic blood pressure | 76 mm[Hg] | 8462-4 | S |
| 2026-07-21 | Heart rate | 74 /min | 8867-4 | S |
| 2026-07-21 | Respiratory rate | 14 /min | 9279-1 | S |
| 2026-07-21 | Body temperature | 36.6 Cel | 8310-5 | S |
| 2026-07-21 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 % | 59408-5 | S |
| 2026-06-23 | Body height | 160 cm | 8302-2 | S |
| 2026-06-23 | Body weight | 90.4 kg | 29463-7 | S |
| 2026-06-23 | Body mass index (BMI) [Ratio] | 35.3 kg/m2 | 39156-5 | S |
| 2026-06-23 | Systolic blood pressure | 122 mm[Hg] | 8480-6 | S |
| 2026-06-23 | Diastolic blood pressure | 78 mm[Hg] | 8462-4 | S |
| 2026-06-23 | Heart rate | 84 /min | 8867-4 | S |
| 2026-06-23 | Respiratory rate | 16 /min | 9279-1 | S |
| 2026-06-23 | Body temperature | 37.2 Cel | 8310-5 | S |
| 2026-06-23 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 % | 59408-5 | S |
| 2026-06-30 | Body height | 160 cm | 8302-2 | S |
| 2026-06-30 | Body weight | 90 kg | 29463-7 | S |
| 2026-06-30 | Body mass index (BMI) [Ratio] | 35.2 kg/m2 | 39156-5 | S |
| 2026-06-30 | Systolic blood pressure | 120 mm[Hg] | 8480-6 | S |
| 2026-06-30 | Diastolic blood pressure | 78 mm[Hg] | 8462-4 | S |
| 2026-06-30 | Heart rate | 76 /min | 8867-4 | S |
| 2026-06-30 | Respiratory rate | 14 /min | 9279-1 | S |
| 2026-06-30 | Body temperature | 36.6 Cel | 8310-5 | S |
| 2026-06-30 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 % | 59408-5 | S |
Social, functional, and mental status
Social history
- S Directs a large public authority responsible for major building works and long-distance trade missions; long days, many public appearances
- S Lives in the city with household staff; has an adult child. Supports: a small circle of trusted advisers, her household, and work she cares about
- S Tobacco: never. Alcohol: a glass of beer or wine at formal dinners, about twice a month. No drug use
- S Diet: large evening meals at official functions, sweet tea and dates through the day; little time to plan meals
- S Activity: walks when she inspects building sites; knee pain limits stairs; no regular exercise
- S Dental care: no dental visit for several years; two back teeth lost earlier to gum disease
Functional status
- S Independent; slowed on stairs by knee pain; eating only soft food on the right side for a week
Mental status
- S Composed, direct and well informed; mood 'busy, but well'; PHQ-9 4 and GAD-7 3; no thoughts of self-harm
Allergies and medications
Allergies
- S No known allergy
Medications
- S Ibuprofen 400 mg oral tablet, one tablet by mouth every six hours as needed for dental pain, with food, for up to one week
- S Acetaminophen 500 mg oral tablet, two tablets (1 g) by mouth every six hours as needed for dental pain, alternating with ibuprofen, no more than 3 g a day, for up to one week
- S Metformin extended-release 500 mg tablet, one tablet with the evening meal for one week, then two tablets (1000 mg) with the evening meal
- S Diclofenac sodium 1% gel, 4 g to each painful knee up to four times a day as needed
- S Chlorhexidine gluconate 0.12% oral rinse, 15 mL swished for 30 seconds and spat out twice daily for two weeks after the extraction
- S Semaglutide 0.25 mg subcutaneous injection once weekly (starting dose, planned for four weeks)
- S Semaglutide 0.5 mg subcutaneous injection once weekly (maintenance dose for now)
- S Atorvastatin 20 mg oral tablet, one tablet by mouth daily
- S Nitrofurantoin monohydrate/macrocrystals 100 mg capsule, one capsule by mouth twice daily with food for five days
Procedures and immunizations
Procedures
- S Panoramic radiograph (orthopantomogram) with a periapical film of the lower left molars
- S Incision and drainage of the buccal vestibular abscess of tooth 19, intraoral approach, under local anesthesia
- S Extraction of the non-restorable lower left first molar (tooth 19) under local anesthesia
- S Advance care planning conversation, about 20 minutes
- S Comprehensive diabetic foot examination with 10-g monofilament, vibration and pulses
- S Retinal photography of both eyes, read by an ophthalmologist
- S Scaling and root planing of all teeth by the dental team, under local anesthesia, over two appointments
- S Screening mammography, both breasts
Immunizations
- S 2026-06-30: Pneumococcal conjugate vaccine, 20-valent (PCV20), single dose for an adult with diabetes
- S 2026-06-30: Tetanus, diphtheria, and acellular pertussis vaccine (Tdap)
- S 2026-06-30: Hepatitis B vaccine (HepB-CpG), dose 1 of 2
Past medical history
True biography with historical dates; not part of the synthetic care timeline.
Family history
No family medical history is documented in the logged sources. Family history of real relatives is never synthesized.
Care-plan goals
| Goal | Target date | Status | Outcome |
|---|---|---|---|
| Dental infection drained and the tooth removed within 24 hours, with no spread of infection | 2026-04-15 | completed | Drained and extracted the next day; no spread |
| Hemoglobin A1c below 7% within four months | 2026-07-21 | completed | A1c 6.6% at fourteen weeks |
| LDL cholesterol below 100 mg/dL on a statin | 2026-07-21 | completed | LDL 76 mg/dL on atorvastatin |
| Periodontal therapy completed and three-monthly maintenance arranged | 2026-07-21 | completed | Scaling and root planing completed; maintenance every three months |
| Climb stairs at the building sites with less knee pain, and walk 150 minutes a week | 2026-07-21 | active | Walking about 120 minutes a week; knee pain on stairs eased |
Interventions
| Intervention | Status | Guideline |
|---|---|---|
| Dental pain and infection safety today: ibuprofen 400 mg with acetaminophen 1 g, alternating, for up to a week, and no opioid; no antibiotic, because the swelling is localized, there is no fever above 38 °C, no trismus and no spread, and drainage is arranged within 24 hours; go to the emergency department at once for swelling spreading to the eye, the floor of the mouth or the neck, difficulty swallowing or breathing, trouble opening the mouth, or a fever | completed | GL-ADA-DENT-PAIN-2024, GL-ADA-DENT-ABX-2019 |
| Urgent oral and maxillofacial surgery consultation within 24 hours for imaging, drainage of the abscess and extraction or other definitive treatment of the broken molar, with an assessment of her gums | completed | GL-ADA-DENT-ABX-2019, GL-EFP-IDF-2018 |
| Type 2 diabetes: metformin extended-release, started slowly; diabetes self-management education and medical nutrition therapy in the clinic's program; A1c every three months until at goal; eye screening, a comprehensive foot examination and kidney tests at diagnosis and yearly; blood pressure goal below 130/80; sick-day rules for metformin; endocrinology only if the A1c is not at goal by six months | completed | GL-ADA-2026, GL-CMID-2026 |
| Weight and health without stigma: person-first language, weight discussed only with her permission, goals she sets for strength and movement, and the medicines that lower both glucose and weight (GLP-1 receptor agonists) explained for her to consider | completed | GL-ADA-OB-2026 |
| Knee osteoarthritis: a walking and strengthening program, diclofenac gel as needed, and a cane or knee support for long site visits if helpful; no imaging needed for a clinical diagnosis | completed | GL-ACR-OA-2019, GL-CMID-2026 |
| Mood screening: PHQ-9 and GAD-7 at intake and at the end of the episode | completed | GL-USPSTF-DEP-2023 |
| Periodontitis and the abscess: chlorhexidine rinse for two weeks after the extraction; scaling and root planing of all teeth by the dental team about six weeks after the extraction, then periodontal maintenance every three months; the two-way link with diabetes explained (periodontal treatment can lower A1c, and better glucose control helps the gums heal) | completed | GL-EFP-IDF-2018, GL-AAP-EFP-2018 |
| Semaglutide once weekly, 0.25 mg for four weeks, then 0.5 mg, with small meals and stopping eating when full to limit nausea; chosen with her for glucose and weight after the dental infection had settled; an SGLT2 inhibitor is not indicated without kidney or heart disease; muscle-strengthening exercise and enough protein to protect muscle and bone as weight falls | completed | GL-ADA-2026, GL-ADA-OB-2026 |
| Cardiovascular risk: atorvastatin 20 mg daily (moderate intensity), as advised for adults 40 to 75 with diabetes; lipids and ALT at about eight to twelve weeks | completed | GL-ADA-CV-2026, GL-CMID-2026 |
| Acute cystitis: nitrofurantoin for five days after a urine culture; fluids; metformin continued while she eats and drinks normally, and paused if she vomits or cannot keep fluids down; the semaglutide step up to 0.5 mg delayed one week; return at once for fever, flank pain, vomiting or symptoms not better in 48 hours | completed | GL-IDSA-CYSTITIS-2011, GL-ADA-2026 |
| Cancer screening by age: screening mammography (every two years from 40), fecal immunochemical test yearly or colonoscopy (from 45), and primary HPV testing every five years (30 to 65); no search for bone cancer, because nothing in her history, examination or blood tests points to one; bone health through weight-bearing and strengthening exercise, calcium from food and adequate vitamin D, with bone density testing at 65 or sooner if a risk factor appears | completed | GL-USPSTF-BRCA-2024, GL-USPSTF-CRC-2021, GL-USPSTF-CERV-2018 |
Planned encounters
- 2026-04-14 — New patient visit for a painful swollen jaw from a suspected dental abscess, with diabetes found on screening; urgent oral and maxillofacial surgery referral (ENC-001)
- 2026-04-15 — Oral and maxillofacial surgery consultation with drainage and extraction of the abscessed molar, diagnosis of periodontitis, and diabetes review (ENC-002)
- 2026-05-26 — Six-week review: healing, diabetes, cardiovascular risk, eye and foot screening, and the start of semaglutide (ENC-003)
- 2026-06-23 — Same-day sick visit for acute cystitis in a woman with new type 2 diabetes (ENC-005, unscheduled)
- 2026-06-30 — Periodic adult preventive visit (ENC-006)
- 2026-07-21 — Fourteen-week review: A1c, lipids, weight, periodontal therapy, knees, and screening results (ENC-004)
Supporting documents
- History and physical
- Progress note 01
- Progress note 02 — Focused Visit (Follow-up)
- Progress note 03 — Focused Visit (Follow-up)
- Progress note 04 — Sick Visit
- Progress note 05 — Preventive Visit
- Progress note 06 — Focused Visit (Care-plan review)
- Oral and Maxillofacial Surgery referral
- Oral and Maxillofacial Surgery consultation
- Patient care plan
- Teaching note
- Provenance CSV
C-CDA note documents
Each link opens a readable copy; the XML beside it is the exchange file.
- History and physical (XML)
- Progress note 01 (XML)
- Progress note 02 — Focused Visit (Follow-up) (XML)
- Progress note 03 — Focused Visit (Follow-up) (XML)
- Progress note 04 — Sick Visit (XML)
- Progress note 05 — Preventive Visit (XML)
- Progress note 06 — Focused Visit (Care-plan review) (XML)
- Oral and Maxillofacial Surgery referral (XML)
- Oral and Maxillofacial Surgery consultation (XML)
Sources
Review status
| Review | Status | Notes |
|---|---|---|
| schema validation | not_started | Run scripts/build.ps1 -Conformance. |
| clinical review | not_started | Awaiting clinician review; check withholding antibiotics for a localized abscess with drainage the next day in a woman with newly found diabetes, the diagnosis of diabetes from two results in one sample, metformin then semaglutide rather than an SGLT2 inhibitor, the statin, periodontal staging and grade, and the decision not to look for bone cancer. |
| provenance review | not_started | Dorman's Oriental Institute essay, a Metropolitan Museum of Art collection record, a British Museum newsletter, the Archaeology magazine report on KV60A, the 2016 review of royal mummy identifications (abstract) and the University of Bonn press release logged. No peer-reviewed paper on the KV60A CT findings was found; the Met and Smithsonian essays could not be fetched. |
| safe messaging review | not_started | Findings on the mummy are graded R because the identification is debated. Weight is discussed in person-first language and only with her permission. Ancient Egyptian culture is described plainly, without exoticizing. |
Comments and corrections
Sign in with GitHub to comment on this record. To report a specific error, ideally with a source, use the feedback form; each report becomes a tracked issue.
Comments appear on the online version of this page.